About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

TERMINATEDPhase 2

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination with Pembrolizumab As a First-line Treatment for Subjects with PD-L1 Positive Advanced Non-Small Cell Lung Cancer

NCT04515979•MedPacto, Inc.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Vactosertib 300 mg BID and pembrolizumab 200 mg IV

Locations

1

South Korea

Locations (1)

Samsung Medical Center

Seoul, South Korea

Key Dates

Start Date

December 17, 2020

Primary Completion Date

August 5, 2024

Completion Date

August 5, 2024

Last Updated

December 9, 2024

Related Studies

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 1

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923

Carcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma+3 more

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566

Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Cancer+4 more

RECRUITINGPhase 2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076

Carcinoma, Non-Small-Cell Lung

View all related studies

Sponsors

Lead Sponsor

MedPacto, Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions